Opendata, web and dolomites

SAPHIRE SIGNED

Securing Adoption of Personalised Health in REgions

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SAPHIRE" data sheet

The following table provides information about the project.

Coordinator
VLAAMSE GEWEST 

Organization address
address: AVENUE DU PORT 88
city: BRUSSEL
postcode: 1000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 1˙853˙813 €
 EC max contribution 1˙778˙813 € (96%)
 Programme 1. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme CSA
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VLAAMSE GEWEST BE (BRUSSEL) coordinator 831˙250.00
2    STICHTING EUROBIOFORUM NL (VLAARDINGEN) participant 408˙813.00
3    REGIONAL AGENCY FOR PUBLIC HEALTH AND SOCIAL WELL-BEING UK (BELFAST) participant 381˙250.00
4    EIT HEALTH INNOSTARS EV DE (GARCHING) participant 157˙500.00

Map

 Project objective

SAPHIRE or the consortium for Securing Adoption of Personalised Health in REgions:

The consortium eSAPHIRE or the consortium for Securing Adoption of Personalised Health in REgions: The consortium engages to help structuring the application of personalised medicine (PM) at regional level and contribute to the implementation and reach of the International Consortium on Personalised Medicine (ICPerMed) to develop its roadmap and Action Plan, while taken regional specific needs into account. Efforts will be taken to express the regional voice within ICPerMed. The activities will include the establishment and support of networking between regions and interregional cooperation, and in particular linking remote or sparsely populated regions with regions harbouring critical mass of medical and PM expertise, while taking into account broader socio-economic and cultural aspects. The network will cover regional policy and decision makers, opinion leaders, regulatory agencies, regional development agencies, cluster organisations, patient organisations and regional knowledge institutions, healthcare actors, ... and will bring regional strengths, needs and barriers to the attention of national and European level. Based on a thorough mapping exercise and addressing specific regional needs, while taken the different levels of PM adoption into account, a modular regional roadmap for PM implementation will be developed. Actions will be taken to support interregional collaborations in the field of PM and identify opportunities for funding or investment by the framework programme, the structural funds or the EIB, whereby efforts will be taken to link remote and sparsely populated regions to regions that are more advanced in PM implementation. Alignment will also be made to smart specialisation initiatives focussing on PM. The integrated approach of SAPHIRE should accelerate the implementation of PM across the European regions, thereby accelerating the uptake of PM in general.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAPHIRE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAPHIRE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.6.)

EBRA (2018)

European Brain Research Area

Read More  

SINO-EU-PerMed (2020)

Widening Sino‐EU policy and research cooperation in Personalised Medicine

Read More  

PERMIT (2020)

PERsonalised MedicIne Trials

Read More